Your Article Summary
See Latest ArticlesEffects of ACE inhibition on proximal tubule sodium transport
Renal Physiology, 03/10/06
Angiotensin-converting enzyme (ACE) inhibitors such as captopril, which block ANG II formation, are commonly used for treatment of hypertension...In summary, captopril can rapidly depress PT reabsorption in the absence of a change in GFR or BP and provokes the redistribution of a set of transporters and transporter-associated proteins that likely participate in the decrease in PT reabsorption and may also contribute to the blood pressure-lowering effect of ACE inhibitors
Related Articles
Renal Function in Glycogen Storage Disease Type I, Natural Course, and Renopreservative Effects of ACE Inhibition
Clinical Journal of the American Society of Nephrology, 11/16/09
Relevance Score: 89%
Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
Journal of the American Society of Nephrology, 11/20/09
Relevance Score: 88%
Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect
Bipolar Disorders, 11/24/09
Relevance Score: 83%
Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: Inhibition of interleukin-1beta-induced nuclear factor-kappaB-mediated inflammation and apoptosis
Arthritis Research & Therapy, 11/11/09
Relevance Score: 83%
Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
International Journal of Cancer, 11/10/09
Relevance Score: 83%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09
Use of psychotropic drugs and analgesics among users of antiobesity drugs - a population based study
Pharmacoepidemiology and Drug Safety, 12/16/09
Measuring exacerbations in obstructive lung disease
Pharmacoepidemiology and Drug Safety, 12/16/09